Literature DB >> 31128567

Fatal intoxication of a regular drug user following N-ethyl-hexedrone and ADB-FUBINACA consumption.

Katalin Kovács1, Éva Kereszty2, Róbert Berkecz3, László Tiszlavicz4, Éva Sija1, Tímea Körmöczi3, Nikolett Jenei5, Hajnal Révész-Schmehl5, László Institóris1.   

Abstract

In Hungary, N-ethyl-hexedrone (NEH) was the most frequently seized stimulant designer drug in 2017, while among synthetic cannabinoids ADB-FUBINACA and AB-FUBINACA were the most popular. Symptoms of intoxication by these substances are well known but less is known about the pathology of overdose-related death. NEH-induced fatal intoxication has not been described in the literature and knowledge surrounding the particular circumstances of death could be useful better public education of risk and more adequate treatment of overdose patients. In this report, we characterize the case of a 23-year-old male regular drug user who died a few hours after NEH and ADB-FUBINACA consumption. His medical history showed arrhythmia in childhood, and some seizures. Autopsy found he had a BMI of 42.9, a hypertrophic and dilated heart, severe atherosclerosis of the valves, coronaries and the arteries, and edema of the internal organs. Histology confirmed those findings. Postmortem blood levels of NEH were 285 ng/ml, along with 0.08 ng/ml ADB-FUBINACA and five ADB-FUBINACA metabolites. Based on the blood concentrations measured in suspected drug users (≤83.9 ng/ml) we hypothesize that NEH intoxication was the cause of death in this case, with heart disease being a co-factor and that the synthetic cannabinoid effect might have been accompaniment. This case also offered the opportunity to identify the metabolites of ADB-FUBINACA in the blood. We identified metabolites in the post-mortem blood by comparing them to human liver microsomal enzyme metabolites in vitro. Three major and two minor metabolites were found in the blood, of which two could only be derived from ADB-FUBINACA, as opposed to other cannabinoids. The case highlights the importance of the complex analysis of drug related deaths by medico-legal autopsy, histopathology and toxicology.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  ADB-FUBINACA; ADB-FUBINACA metabolites; Fatal outcome; N-Ethyl-hexedrone; Regular drug user

Mesh:

Substances:

Year:  2019        PMID: 31128567     DOI: 10.1016/j.jflm.2019.04.012

Source DB:  PubMed          Journal:  J Forensic Leg Med        ISSN: 1752-928X            Impact factor:   1.614


  6 in total

1.  Analytical Methodologies for the Characterization and Analysis of the Parent Compound and Phase I Metabolites of 4F-MDMB-BICA in Human Microsome, Urine, and Blood Samples.

Authors:  Tímea Körmöczi; Éva Sija; László Institóris; Éva M Kereszty; István Ilisz; Róbert Berkecz
Journal:  J Anal Toxicol       Date:  2021-01-06       Impact factor: 3.367

Review 2.  Overview of Synthetic Cannabinoids ADB-FUBINACA and AMB-FUBINACA: Clinical, Analytical, and Forensic Implications.

Authors:  Carolina Lobato-Freitas; Andreia Machado Brito-da-Costa; Ricardo Jorge Dinis-Oliveira; Helena Carmo; Félix Carvalho; João Pedro Silva; Diana Dias-da-Silva
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-25

Review 3.  A review of synthetic cathinones emerging in recent years (2019-2022).

Authors:  Patryk Kuropka; Marcin Zawadzki; Paweł Szpot
Journal:  Forensic Toxicol       Date:  2022-09-15       Impact factor: 2.541

Review 4.  An updated review on synthetic cathinones.

Authors:  Jorge Soares; Vera Marisa Costa; Maria de Lourdes Bastos; Félix Carvalho; João Paulo Capela
Journal:  Arch Toxicol       Date:  2021-06-08       Impact factor: 5.153

Review 5.  Designer drugs: mechanism of action and adverse effects.

Authors:  Dino Luethi; Matthias E Liechti
Journal:  Arch Toxicol       Date:  2020-04-06       Impact factor: 5.153

6.  Fatal N-Ethylhexedrone Intoxication.

Authors:  Ewa Domagalska; Laura Banaszkiewicz; Mateusz Kacper Woźniak; Marzena Kata; Beata Szpiech; Michał Kaliszan
Journal:  J Anal Toxicol       Date:  2021-07-10       Impact factor: 3.367

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.